170635 ⎘
Assays involving biological materials from specific organisms or of a specific nature; Enzymes; Proenzymes; Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7) Phosphotransferases in general
Sub-classes:MOLECULAR PROFILING OF TUMORS
#2APPARATUS FOR MEASURING ENZYME ACTIVITY USING SUBSTRATE-IMMOBILIZED CARRIER WITH NON-UNIFORM SUBSTRATE IMMOBILIZATION DENSITY AND METHOD THEREOF
#3COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID
#4AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#5MOLECULAR PROFILING OF TUMORS
#6FUSION PROTEINS AND METHODS THEREOF
#7PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#8COMPANION METHODS AND KITS FOR IL-2-BASED THERAPIES AND MESENCHYMAL STEM CELL-BASED THERAPIES
#9Supermere Nanoparticles and Methods of Isolation and Use Thereof
#10BIOPHYSICAL PLATFORM FOR DRUG DEVELOPMENT BASED ON ENERGY LANDSCAPE
#11BIOMARKERS FOR PROGNOSIS OF EARLY ONSET PREECLAMPSIA
#12Crenolanib for Treating FLT3 Mutated Proliferative Disorders
#13RATIOS OF sFlt-1 TO P1GF OR ENDOGLIN TO P1GF AS BIOMARKERS FOR PREECLAMPSIA RELATED ADVERSE OUTCOMES AFTER BIRTH
#14METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE
#15METHODS TO IDENTIFY AND TREAT SUBJECTS HAVING CORTICOSTEROID-RESISTANT INFLAMMATORY DISEASES
#16FUSION PROTEINS AND METHODS THEREOF
#17FUSION PROTEINS AND METHODS THEREOF
#18MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
#19BICYCLIC INHIBITORS OF IRAK
#20METHODS OF TREATING MALIGNANT GLIOBLASTOMA
#21METHODS AND COMPOSITIONS RELATING TO BIOMARKERS FOR NEURODEGENERATIVE DISEASES
#22THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, AND ASSOCIATED BIOMARKERS BASED ON TRK-B
#23METHOD FOR LABELING INTRACELLULAR AND EXTRACELLULAR TARGETS OF LEUKOCYTES
#24TARGETING DNA-PKCS AND B7-H1 TO TREAT CANCER
#25Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same
#26Active Alpha-5-Beta-1 Integrin As A Biomarker For Enhancing Tumor Treatment Efficacy
#27MOLECULAR PROFILING OF TUMORS
#28Immuno-optomagnetic point-of-care assay and method for detection of analyte using multifunctional optomagnetic quantum dot nanqcrystals (MQDs)
#29Compositions and methods for modulating kinase activity
#30PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#31Crenolanib for treating FLT3 mutated proliferative disorders
#32METHODS AND DEVICES FOR THE PRODUCTION AND DELIVERY OF BENEFICIAL FACTORS FROM STEM CELLS
#33Modular point-of-care devices, systems, and uses thereof
#34RAF1 FUSIONS
#35SYSTEMS AND METHODS FOR IDENTIFYING SUBTYPE, PROGNOSIS, AND MONITORING OF BREAST CANCER
#36Methods to identify and treat subjects having corticosteroid-resistant inflammatory diseases
#37METHOD FOR TREATING CANCER
#38Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same
#39Anti-kit antibodies and uses thereof
#40METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#41TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD
#42CYSTEINE-REACTIVE LIGAND DISCOVERY IN PROTEOMES
#43COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID
#44KITS SUITABLE FOR USE IN ELECTROCHEMILUMINESCENCE METHODS AND METHODS OF EFFECTING A SPECIFIC-BINDING NON-WASH ASSAY
#45Target for diabetes treatment and prevention
#46MEK1 mutation conferring resistance to RAF and MEK inhibitors
#47TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD
#48Crenolanib for treating FLT3 mutated proliferative disorders
#49Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth
#50Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
#51Method for determining sensitivity of cyclin-dependent kinase 4/6 inhibitor
#52Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
#53Fusion proteins and methods thereof
#54METHODS OF IDENTIFYING INDIVIDUALS AT INCREASED RISK OF LUNG CANCER
#55Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
#56METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS
#57Fusion proteins and methods thereof
#58RAF1 FUSIONS
#59Kit for monitoring, detecting and staging GVHD
#60METHOD
#61Targeting DNA-PKCS and B7-H1 to treat cancer
#62METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER
#63Fusion proteins and methods thereof
#64Method of treating melanoma using an inhibitor of an atypical protein kinase C
#65MOLECULAR PROFILING OF TUMORS
#66Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#67NTRK2 FUSIONS
#68FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME
#69Cell response assay for cancer and methods of producing and using same
#70Membrane span-kinase fusion protein and the uses thereof
#71SRM/MRM assay for the tyrosine-protein kinase receptor UFO(AXL) protein
#72Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer
#73Stem cell modulation II
#74Crenolanib for treating FLT3 mutated proliferative disorders
#75Methods of detecting and treating a tumor expressing pT346 PDK1
#76AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#77REGULATORS OF ANAPLASTIC LYMPHOMA KINASE AND USES THEREOF
#78MK2 inhibitors and uses thereof
#79Methods of treating by administering anti-kit antibodies
#80Compositions and methods for detecting mutations in JAK2 nucleic acid
#81Compositions and methods for treating estrogen-related medical disorders
#82Methods to identify and treat subjects having corticosteroid-resistant inflammatory diseases
#83Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
#84FLT3 receptor antagonists for the treatment or the prevention of pain disorders
#85TPM4-ALK fusion protein and composition for diagnosing cancer
#86Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
#87Methods for molecular classification of fatty liver by high-throughput protein post-translational modifications
#88Kits suitable for use in electrochemiluminescence methods and methods of effecting a specific-binding non-wash assay
#89Modular point-of-care devices, systems, and uses thereof
#90CHEMICAL SYNTHESIS
#91Modular point-of-care devices, systems, and uses thereof
#92MEK1 mutation conferring resistance to RAF and MEK inhibitors
#93Compositions and methods for treating estrogen-related medical disorders
#94Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#95Methods and devices for the production and delivery of beneficial factors from adipose-derived stem cells
#96Treatment with an IL-2 based therapy
#97IMIDAZOPYRAZINE SYK INHIBITORS
#98Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
#99ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY
#100FUSION PROTEINS AND METHODS THEREOF
#101Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#102Crenolanib for treating FLT3 mutated proliferative disorders
#103CIRCULATING TUMOR CELL ASSAY
#104INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION
#105Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways
#106Biophysical platform for drug development based on energy landscape
#107Method of treating melanoma using an inhibitor of an atypical protein kinase C
#108FLT3 receptor antagonists for the treatment or the prevention of pain disorders
#109Cardiomyocyte marker
#110N-substituted 4-aminoquinazoline derivatives and methods of use
#111IMMUNO-MALDI TO MEASURE AKT1 AND AKT2 PHOSPHORYLATION
#112PKC delta inhibitors for use as therapeutics
#113Diagnosis and treatment of breast cancer
#114Methods for generating engineered enzymes
#115Methods for predicting response of triple-negative breast cancer to therapy
#116Methods for treating Her2-positive breast cancer
#117Treating chronic myelogenous leukemia (CML)
#118Targeting DNA-PKcs and B7-H1 to treat cancer
#119Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
#120Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#121Methods for breast cancer treatment
#122Methods of treating a kit-associated cancer by administering anti-kit antibodies
#123CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME
#124METHODS AND PRODUCTS RELATING TO GSK3ß REGULATION
#125RAF1 fusions
#126SRM/MRM Assay for the Serine/Threonine-Protein Kinase B-RAF (BRAF)
#127Method for the detection of cancer cells by localization of peptides in nucleus as compared to cytoplasm
#128Compositions and methods for treating estrogen-related medical disorders
#129REGULATORS OF ANAPLASTIC LYMPHOMA KINASE AND USES THEREOF
#130Compositions and methods for treating estrogen-related medical disorders
#131RAF gene fusions
#132Treatment or prevention of an intestinal disease or disorder
#133CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
#134INDOLE-LIKE TRK RECEPTOR ANTAGONISTS
#135SRM/MRM assay for the tyrosine-protein kinase receptor UFO (AXL) protein
#136Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
#137Methods and compositions for targeting cancer stem cells
#138Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
#139ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY
#140Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
#141METHOD FOR TREATING CANCER
#142Biomarkers associated with schizophrenia
#143Modular point-of-care devices, systems, and uses thereof
#144KIT FOR MONITORING, DETECTING AND STAGING GVHD
#145Methods and compositions for treating cancer through inhibition of PI3K
#146Modular point-of-care devices, systems, and uses thereof
#147Target for diabetes treatment and prevention
#148KINASE ACTIVITY DETECTION METHODS
#149Herbal Combinations for Treating Eczema
#150METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
#151SIGNALING PATHWAYS IN TISSUES FROM INFLAMMATORY BOWEL DISEASE PATIENTS
#152METHODS FOR DETECTING ALLOSTERIC MODULATORS OF PROTEIN
#153METHODS FOR DETECTING ALLOSTERIC MODULATORS OF PROTEIN
#154Stem cell modulation II
#155Quantifying Her2 protein for optimal cancer therapy
#156Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug
#157Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
#158PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA
#159Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
#160Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#161FGFR gatekeeper mutant gene and drug targeting same
#162METHOD FOR PREDICTING ANTITUMOR EFFICACY OF HSP90 INHIBITOR IN CANCER TREATMENT
#163METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#164ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE
#165Polynucleotides encoding anti-kit antibodies
#166ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION
#167Crenolanib for treating FLT3 mutated proliferative disorders
#168Methods and Kits for Detecting Prostate Cancer Biomarkers
#169Biomarkers for Ovarian Cancer
#170Antibody and aptamer ensemble for cell isolation and enrichment
#171METHODS OF SELECTING AKT AGONISTS OR ANTAGONISTS
#172METHODS FOR DETERMINING THE EFFECTS OF COMPOUNDS ON JAK/STAT ACTIVITY
#173Compositions and methods for detecting mutations in JAK2 nucleic acid
#174NTRK2 fusions
#175Modular point-of-care devices, systems, and uses thereof
#176Modular point-of-care devices, systems, and uses thereof
#177Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
#178Modular point-of-care devices, systems, and uses thereof
#179Cysteine-reactive ligand discovery in proteomes
#180Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
#181Akt-specific capture agents, compositions, and methods of using and making
#182PKC delta inhibitors for use as therapeutics
#183MOLECULAR PROFILING OF TUMORS
#184MOLECULAR PROFILING OF TUMORS
#185MOLECULAR PROFILING OF TUMORS
#186Kits to assay kinase activity
#187METHOD OF ENHANCING HEMATOPOIETIC CELL TRANSPLANTATION
#188MEK1 mutation conferring resistance to RAF and MEK inhibitors
#189Methods of determining response to therapy
#190Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
#191Methods for treating ischemia-reperfusion injury
#192P38 MAPK INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
#193MAP kinase P38 binding compounds
#194Methods of treating fragile X syndrome and related disorders
#195Methods for predicting and improving the survival of colorectal cancer patients
#196MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF
#197Activated HER3 as a marker for predicting therapeutic efficacy
#198Modular point-of-care devices, systems, and uses thereof
#199Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#200SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER
#201Fluorescent probe sensing tyrosine kinase and use thereof
#202Method for determining prognosis of cancer
#203Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection
#204Biomarker PNCK for predicting effect of a dual-targeting agent
#2056-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine
#206Compositions including triciribine and one or more platinum compounds and methods of use thereof
#207Modular point-of-care devices, systems, and uses thereof
#208Methods to identify and treat subjects having corticosteroid-resistant asthma
#209Modular point-of-care devices, systems, and uses thereof
#210METHODS OF EVALUATING RESPONSE TO CANCER THERAPY
#211MK2 inhibitors and uses thereof
#212CDKACT BIOSENSORS-FLUORESCENT POLYPEPTIDE TO PROBE THE ACTIVITY OF CDK/CYCLIN KINASES IN VITRO, IN CELLULO AND IN VIVO
#213Modular point-of-care devices, systems, and uses thereof
#214Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
#215Method for diagnosing neurodegenerative diseases
#216COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF CANCER
#217FLT3 receptor antagonists for the treatment or the prevention of pain disorders
#218Aptamers, multimeric aptamers and uses thereof
#219Methods for detecting allosteric modulators of protein
#220Fully human antibodies and fragments recognizing human c-Met
#221Methods for novel drug discovery, treatment and selective targeting for gefitinib-resistant non-small-cell lung cancer harboring T790M mutation
#222TREATMENT OF CANCER BY TARGETING QUIESCENT CANCER CELLS
#223Compositions and methods for treating estrogen-related medical disorders
#224Composition and method for diagnosis and immunotherapy of prostate cancer
#225METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS
#226Methods of identifying individuals at increased risk of lung cancer
#227DETECTING AND SORTING CELLS OR PARTICLES
#228Phosphorylated Akt-specific capture agents, compositions, and methods of using and making
#229METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER
#230Mutations In Calmodulin Genes
#231Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
#232Anti-phospho-Akt antibodies
#233Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
#234FUSION PROTEINS AND METHODS THEREOF
#235RAF gene fusions
#236CANCER CLASSIFICATION AND METHODS OF USE
#237Dynamic monitoring of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) activity and pathways in living cells using real-time microelectronic cell sensing technology
#238NOVEL CARDIOMYOCYTE MARKER
#239CIRCULATING TUMOR CELL ASSAY
#240Whole blood assay for measuring AMPK activation
#241Compounds and methods of use thereof for treating neurodegenerative disorders
#242DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT BY DETECTING KRAS MUTATION AND RTK EXPRESSION LEVELS
#243COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF CANCER
#244Fluorescent marker for tissue staining containing phosphor-containing nanoparticle and method using same
#245Methods and Compositions for Characterizing Phenotypes Using Kinome Analysis
#246Methods and products relating to GSK3β regulation
#247Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
#248SPARC and methods of use thereof
#249METHODS FOR DIAGNOSING AND TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
#250Compositions and methods for inducing myoblast differentiation and myotube formation
#251METHOD FOR CHARACTERIZING CIRCULATING TUMOR CELLS, AND USE THEREOF IN DIAGNOSIS
#252Methods of detecting Akt3 and administering Ax1 inhibitor
#253Methods for detecting allosteric modulators of protein
#254METHOD FOR THE DIAGNOSIS OF MAMMALS
#255Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
#256Parkinson's Disease Biomarker
#257Compositions and methods for detecting nitration of PKG-1α and methods of use thereof
#258Brain somatic mutations associated to epilepsy and uses thereof
#259Methods and Kits for Analyzing Biomarkers in a Signal Transduction Pathway
#260METHODS AND BIOMARKERS FOR DETECTION AND TREATMENT OF MATURE T-CELL LEUKEMIA
#261Method and kit for analyzing protein-protein interaction using nanocluster formation
#262Anaplastic lymphoma kinase (ALK) as an oncogene capable of transforming normal human cells
#263Method of Screening Therapeutic Agent for Treating Inflammatory Diseases
#264Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
#265BIOMARKERS OF RENAL DISORDERS
#266Membrane span-kinase fusion protein and the uses thereof
#267Method for labeling intracellular and extracellular targets of leukocytes
#268Aptamer which selectively binds to ERBB2 receptor and uses thereof
#269Sample processing device with detachable slide
#270Biosensor for detecting RAF/KSR family kinase dimerization and uses thereof
#271Determination of sFlt-1:angiogenic factor complex
#272Methods for detecting allosteric modulators of protein
#273PAS kinase assays
#274System and method for determining individualized medical intervention for a disease state
#275System and method for determining individualized medical intervention for a disease state
#276Kits suitable for use in electrochemiluminescence methods and methods of effecting a specific-binding non-wash assay
#277Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction
#278SRM/MRM assay for the receptor tyrosine-protein kinase erbB-4 protein (HER4)
#279Stratification of pancreatic and ovarian cancer patients for susceptibility to therapy with PTK2 inhibitors
#280Methods and kits that identify tumors responsive to Src inhibitors
#281Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
#282Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
#283Novel binding site of IKK-beta
#284Methods and compositions for detecting the activation state of multiple proteins in single cells
#285Tissue staining method with staining agent containing particle holding plural phosphors
#286c-Src selected reaction monitoring assay
#287ENZYME-LOGIC BIOSENSING
#288FLT3 receptor antagonists for the treatment or the prevention of pain disorders
#289Compositions including triciribine and one or more platinum compounds and methods of use thereof
#290Map kinase kinase kinase kinase 3 (MAP4K3) as a biomarker and therapeutic target for autoimmune disease, cancer, inflammation and IL-17-associated disease
#291Methods for predicting response of triple-negative breast cancer to therapy
#292Measurement of PKA for cancer detection
#293Methods and compositions for detecting the activation state of multiple proteins in single cells
#294Dynamic monitoring of activation of receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
#295METHODS FOR DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS
#296SPLIT-LUCIFERASE C-MYC SENSOR AND USES THEREOF
#297SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER
#298Composition and method for diagnosis and immunotherapy of prostate cancer
#299Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
#300INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION